News coverage about Eyegate Pharmaceuticals (NASDAQ:EYEG) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eyegate Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 45.5835509798409 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Eyegate Pharmaceuticals (EYEG) traded up $0.04 during trading on Monday, reaching $0.64. The company had a trading volume of 72,100 shares, compared to its average volume of 412,852. The firm has a market cap of $10.98, a P/E ratio of -0.54 and a beta of 2.91. Eyegate Pharmaceuticals has a twelve month low of $0.50 and a twelve month high of $3.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.81 and a quick ratio of 0.81.
EYEG has been the topic of several recent research reports. HC Wainwright set a $5.00 price target on Eyegate Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 19th. ValuEngine upgraded Eyegate Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
ILLEGAL ACTIVITY WARNING: “Eyegate Pharmaceuticals (EYEG) Earning Somewhat Positive Press Coverage, Accern Reports” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/19/eyegate-pharmaceuticals-eyeg-earning-somewhat-positive-press-coverage-accern-reports.html.
About Eyegate Pharmaceuticals
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.